In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detected at diagnosis. Using small-molecule inhibitors of MDM2, we provide evidence that miR-192, 194, and 215, which are downregulated in a subset of newly diagnosed MMs, can be transcriptionally activated by p53 and then modulate MDM2 expression. Furthermore, ectopic re-expression of these miRNAs in MM cells increases the therapeutic action of MDM2 inhibitors in vitro and in vivo by enhancing their p53-activating effects. In addition, miR-192 and 215 target the IGF pathway, preventing enhanced migration of plasma cells into bone marrow. The results suggest that these miRNAs are positive regulators of p53 and that their downregulation plays a key role in MM development.
INTRODUCTION
The tumor suppressor p53 is frequently inactivated by mutations or deletions in cancer. p53 acts as a potent transcription factor and can be activated in response to diverse stresses, leading to induction of cell-cycle arrest, apoptosis, or senescence (Junttila and Evan, 2009; Xue et al., 2007) . Although regulation of the p53 pathway is not fully understood at the molecular level, it has been well established that activated p53 suppresses cancer progression, underlining why cancer cells have developed multiple mechanisms to disable p53 function (Danovi et al., 2004; Ventura et al., 2007) . In human tumors that retain wildtype (WT) p53 (Junttila and Evan, 2009; Lane, 2001 ) p53 can be antagonized by murine double minute 2 (MDM2), a negative Significance Therapeutic activation of p53 may be particularly appropriate for treatment of the $50% of hematopoietic malignancies with intact TP53. We describe a signaling pathway in which miR-192, 194 , and 215 are regulators of the MDM2/p53 auto regulatory loop, controlling the balance between p53 and MDM2 expression. Hypermethylation of the miR-194-2-192 cluster promoter in MM cell lines suggests that epigenetic downregulation of these miRNAs, which leads to increased MDM2 mRNA and protein expression, decreases the ability of p53 to downmodulate MDM2 expression, thus tipping the regulatory loop in favor of MDM2. Exploring these miRNAs as enhancers in the pharmacological activation of the p53 pathway in MM cells might open avenues for miRNA-targeted therapies and MM treatment.
regulator of p53 that is also overpriced in many human tumors, offering a therapeutic strategy (Dickens et al., 2009; Brown et al., 2009) . It has been reported that inhibiting MDM2 expression can reactivate p53 in cancer cells, leading to their demise (Dickens et al., 2009; Saha and Chang, 2010) .
TP53 mutation is rarely detected at diagnosis in many hematological cancers such as multiple myeloma (MM), acute myeloid leukemia, chronic lymphocytic leukemia, and Hodgkin's disease (HD). Thus, numerous reports have shown that therapeutic induction of p53 might be particularly suitable for the treatment of hematological malignancies (Saha and Chang, 2010) . Among them, multiple myeloma (MM) is a currently incurable plasma cell proliferative disorder that results in considerable morbidity and mortality (Kuehl and Bergsagel, 2002; Fonseca et al., 2009) . MM develops from a benign condition called monoclonal gammopathy of undetermined significance (MGUS) (Weiss et al., 2009) . Individuals with MGUS often remain stable for years and do not require treatment. However, for unknown reasons, this benign condition can evolve into MM at a rate of $1% per year, with some MMs developing after many years (Kuehl and Bergsagel, 2002; Fonseca et al., 2009) .
In MGUS and in the majority of newly diagnosed MM cases TP53 is WT (Kuehl and Bergsagel, 2002; Chng et al., 2007) and the protein is rarely detectable (Stuhmer and Bargou, 2006) . Interestingly, in MM cells, expression of p53 protein levels can be rescued by antagonizing MDM2. Several reports have focused on the p53-mediated apoptotic pathway, upon endogenous p53 protein re-expression by the small-molecule MDM2 antagonists (Nutlins) and target genes which may be involved in p53-dependent apoptosis in MM cells have been identified (Stuhmer and Bargou, 2006) .
MicroRNAs are an abundant class of short, non-proteincoding RNAs that mediate the regulation of target genes posttranscriptionally and that have emerged as master regulators in diverse physiologic and pathologic processes (Bartel, 2004) , and oncogenesis (Croce, 2008) . Recently, microRNAs (miRNAs) have been reported to be directly transactivated by p53 (He et al., 2007) . miRNAs have also been shown to target p53 and/or components of p53 regulatory pathways, thereby directly and/or indirectly affecting its activities (Park et al., 2009; Zhang et al., 2009) . We previously published the global miRNA-expression profiles of MM and MGUS and contrasted these profiles with those of normal plasma cells (PCs) (Pichiorri et al., 2008) . The findings defined a miRNA signature related to expression and regulation of proteins associated with malignant transformation of PCs, such as p53 (Pichiorri et al., 2008) . We have now examined the regulation and functional roles of miRNAs in MM development using small-molecule inhibitors of MDM2.
RESULTS

Identification of p53-Regulated miRNAs in MM
To determine if miRNAs are regulated by p53 in MM cells, we performed custom microarray analysis with an expanded set of probes capable of assaying the expression of more than 500 human miRNAs. Two approaches to compare the effect of p53 level on miRNA expression were used. We first assessed a specific signature associated with the presence of WT TP53 in MM cell lines as shown in Figure 1A and Table S1 available online. Six MM cell lines were used in the analyses: MM1s, NCI-H929, and KMS28BM which retain and express WT TP53; RPMI-8226, U266 with mutant TP53; and JJN3 that does not express TP53 mRNA. Western blot analysis of these cells shows their p53 and MDM2 steady-state protein levels, respectively ( Figure S1A ). Genomic and cDNA sequence analyses confirmed the presence of WT TP53 cells in association with higher MDM2 mRNA expression ( Figure S1B ). Several differentially expressed miRNAs were identified (Table S1 ). Some of these miRNAs, such as those of miR-34 family, have been found to be associated with p53 status in other human malignancies (Hermeking, 2010) . In the second approach, we performed miRNA microarray analysis in MM1s cells treated with or without Nutlin-3a (10 mM), a small-molecule inhibitor of MDM2 ( Figure 1B) . In response to Nutlin-3a treatment, we identified expression of distinct miRNAs associated with p53 activation ( Figure 1B ; Table S2 ). Only two miRNAs were upregulated in both analyses: miR-34a and miR-194 (Figures 1A and 1B; Tables S1 and S2 ). These results not only confirm upregulation of miR-34a as a function of wildtype (WT) p53 status (He et al., 2007) but also point to strong upregulation of miR-194 by p53 (Tables S1 and S2; Figures 1A  and 1B) . The significant upregulation of miR-192 and miR-215 after p53 re-expression through Nutlin-3a treatment is especially interesting because they are located, together with miR-194, in two related microRNA clusters, the miR-194-2-192 cluster at 11q13.1 and the miR-215-194-1 cluster at 1q41.1 (Table S2) , and have the same seed sequence. Genomic locations of these two clusters have been reported to be important for MM (Fonseca et al., 2009) . miR-194 also has the same mature sequence regardless its expression cluster and miRNAs of the same cluster are usually expressed together (Garofalo et al., 2009; Ventura et al., 2008) .
p53 Induces the Expression of miR-192, 194, and 215 To confirm the microarray data, we first tested by q-RT-PCR for the presence of miR-34a, miR-194, and its cluster associate, miR-192 and 215, in WT TP53 compared with Mut TP53 cells ( Figure S1C ). WT TP53 cells retained higher expression of miR-34a, miR-194, and miR-192 (Figure S1C ), but did not show expression of miR-215, suggesting that the 11q13.1 miR-194-2-192 cluster is associated with WT TP53 status in MM cells. To determine the kinetics of p53 activation, we treated MM1s cells with 10 mM Nutlin-3a for different duration of time. p53 was barely detectable by immunoblotting at 6 hr but increased after 12, 18, and 24 hr of treatment and remain constant at 30-36 hr ( Figure 1C ). The induction of p53 was also associated with MDM2 accumulation, p21 expression, and c-MYC downregulation after 12 hr of treatment ( Figure 1C ). The expression of p21-encoding CDKN1A, a p53 target gene, was also assessed by RT-PCR ( Figure 1D ). By northern blot and qRT-PCR analysis, we also studied the kinetics of miRNA activation during p53 upmodulation in MM1s cells. The kinetics of miR-34a, miR-194, miR-192 , and miR-215 expression ( Figure 1E ) were directly correlated with p53 protein upregulation and p21 activation ( Figures 1C and 1D ), while for miR-15 and miR-29a/b the dynamics of expression appeared more related to downregulation of their repressor c-MYC as expected  Figures S1D and S1E; Figure 1D ), than to p53 activation. To confirm the responsiveness of these miRNAs to p53, cell lines Figure 1 . Identification of p53-Regulated miRNAs in MM Cells (A) Overview of two-way (genes against samples) hierarchical cluster (Euclidean distance) of 6 MM cell lines in duplicate using the genes that vary the most between samples. As shown, the clustering is mainly determined by the presence of WT TP53 expression (NCI-H929, MM1s, and KMS28BM) or mutant/null TP53 (U266, RPMI-8226, JJN3) in the cell lines. In magnification are reported the miRNAs upregulated more than 3-fold in WT TP53 cell lines with p < 0.001. See also Figure S1 and Table S1 .
(B) Overview of two-way of MM1s cells treated with 10 mM Nutlin-3a overnight (biological quadruplicate) and with DMSO (biological triplicate) using the genes that vary the most between samples. As shown, the clustering is mainly determined from the Nutlin-3a treatments and DMSO treatment. Color areas indicate relative expression of each gene with respect to the gene median expression (red above, green below the median value, and black, samples with signal intensity to background of 2 or less). See also Figure S1 and Table S2 . -194, miR-192, miR-215 , and miR-34a in MM1s cells after Nutli-3a treatment, measured by qRT-PCR and northern blot analysis. Lines represent relative fold changes between DMSO and Nutlin-3a treatment ±SD. RNU44 (qRT-PCR) and RNU6B (northern blot) expression was used for normalization. See also Figure S1 . (F-H) miR-192, miR-215 and miR-194 relative expression in CD138+ PCs from healthy, MGUS, and MM samples (see Table S3 ) were determined by Taqman q-RT PCR assay. Each data sample was normalized to the endogenous reference RNU44 and RNU48 by use of the 2-ct method. The relative expression values were used to design box and whisker plots. Dots in the boxes indicate outlier points. Kruskal-Wallis analysis assessed that the three miRNAs were differentially expressed among MGUS samples versus MM PCs samples of the Bartlett test p % 0.001. miR-192, 194 , and 215 Target MDM2 in Myeloma Cells with varying TP53 status were treated with Nutlin-3a or vehicle (DMSO), followed by qRT-PCR to monitor miRNA levels upon p53 activation (Figures S1F-S1K). Induction of miR-34a, miR-192, miR-215, and miR-194 was detected only in the cell lines treated with Nutlin-3a and harboring WT TP53 (p < 0.001, Figure S1 ). Next, we analyzed induction of these miRNAs, by Nutlin-3a in freshly isolated CD-138+ PCs ( Figure S1L ), from eight bone marrow aspirates of MM patients. Two samples (Pt-1 and Pt-2) exhibited TP53 deletion by FISH analysis, while 6 (Pt-3 to Pt-8) retained TP53 genes (Table S3 ). We detected induction of p53, miR-34a, 192, 194, 215 after 12 hr of Nutlin-3a treatment (Figures S1M-S1O) in TP53 WT samples, in association with different levels of CDKN1A mRNA activation ( Figure S1O ). Furthermore, to determine if these miRNAs are relevant in MM pathogenesis, we analyzed the expression of miR-194, 192 , and 215 in a panel of CD138+ PCs obtained from newly diagnosed MM patients (n = 33), MGUS (n = 14) patients and normal donors (n = 4) ( -194-2-192 and miR-215-194 -1 clusters, we analyzed the cluster promoter regions. The upstream genomic region close to the transcription start site (TSS) (+1) (Hino et al., 2008) of pri-miR-194-2-192 contains several highly conserved regions among human, mouse, rat, and dog sequences (from À162 to +21 with respect to the TSS). To identify the promoter region responsive to p53 re-expression, we constructed reporter plasmids carrying various genomic sequences around the TSS of the pri-miR-194-2-192 cluster and subjected them to luciferase assay ( Figure 2A ). Bioinformatics search identified a previously reported high score p53 consensus site between À900/À912 bp (Sinha et al., 2008; Song et al., 2008) ; however, this site was not functional for p53 activation since luciferase reporter constructs excluding this region retained full activity (P3-P7) ( Figure 2A ). The region from À245 to +186 bp (P7) had promoter activity comparable to that of the longest regions in MM cells after forced expression of p53 (Figure 2A ), but regions from À125 to +186 bp (P8) Cancer Cell miR-192, 194 , and 215 Target MDM2 in Myeloma Cells and À912 to À245 bp (P10) did not. We identified a p53-responsive element between À245 and À125 bp ( Figure 2B ) because the construct excluding this region was not affected by p53 expression (Figure 2A ). Since conserved regions in a given gene promoter are expected to contain regulatory elements, we focused on the highly conserved region controlling luciferase activity, the region between À161 and À135 bp. Luciferase assay using a construct mutated for each C and G contained in the two decamers of the hypothetical El-Deiry consensus sequence revealed that this unpredicted and previously unpublished region is critical for p53 transcriptional activation of the pri-miR-194-2-192 cluster ( Figure 2B ). Indeed, we found that endogenous p53 directly interacts with the core element of the pri-miR-194-2 promoter in MM1s cells, as demonstrated by CHIP assay after 12 hr of Nutlin-3a treatment ( Figure 2C ). As a positive control, we used the p53 consensus site on the miR-34a promoter, while a nonspecific sequence served as negative control ( Figure 2C ). Ectopic expression of p53 activated the promoter of both members of the pri-miR-194-2-192 cluster in MM1s cells ( Figure 2D ). MDM2 siRNA after p53 re-expression in MM1s cells led to higher relative luciferase activity and thus confirmed its dependence on p53 re-activation. Taken together, these data suggest that p53 is a key transcriptional activator of pri-miR-194-2 through directly binding to the core promoter element ( Figure 2D ). We also attempted to identify the promoter and primary transcript of miR-215-194-1 on chromosome 1q41.1, but could not identify the primary transcript initiation point by 3 0 and 5 0 RACE and PCR amplification of the putative transcribed sequences (ESTs); however, we confirmed the previously published consensus site for p53 by CHIP analysis ( Figure S2 ). -192, 194 , and 215 Affect p53-Dependent MM Cell Growth To examine the relevance of p53-mediated regulation of miR-192, 194, and 215 in MM, we first tested whether reintroduction of these miRNAs affected the biology of MM cells. Previous studies (Georges et al., 2008; Braun et al., 2008) showed that such reintroduction induced expression of p21 in different cancer cell lines which carried WT TP53, with a consistent G0/G1 arrest and p53 protein expression. The molecular mechanism of p53 re-expression remained elusive. To confirm this effect in our model, miR-192, miR-194 , and miR-215 were introduced into transfection in WT TP53-cell lines (MM1s, NCI-H929, and KMS28BM), as well as cells with mutated TP53 (RPMI-8226), followed by detection of TP53 and mRNAs of target genes CDKN1A and MDM2, by RT-PCR analysis ( Figure S3 ). We found consistent re-expression of CDKN1A in TP53 WT cells ( Figure S3A ) after transfection, but did not detect any increase in TP53 mRNA ( Figure S3B ). Using MTS assay, we observed significant growth arrest in the cells transfected with miR-192, 215 and a less significant arrest with miR-194 in MM cells carrying WT TP53 ( Figures 3A-3C ), as compared with scrambled sequences. In contrast, we did not detect this effect in RPMI-8226 cells ( Figure 3D ) expressing mutant TP53. Next, we determined if p53-responsive miRNAs interfere with the clonogenic survival of MM cells. MM cells were lentivirus-transduced with miR-192, miR-215, miR-194 and miR-34a, miR-192, and 215 in WT p53 cells suppressed colony formation to an extent comparable to miR-34a, which was used as an internal control. Of note, miR-194 was less effective than miR-215 and miR-192. These miRNAs did not suppress colony formation in RPMI-8226 ( Figures 3E and 3F ) or U266 cells (F.P., S.-S.S., C.M.C, unpublished data), while miR-34a did exhibit colony suppression in these mutant TP53 cells, confirming its p53-independent apoptotic action (Hermeking, 2010) .
Cancer Cell
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To further explore the p53-dependent mechanism(s) of miR-192, 215, and 194 interferences with cell growth and colony formation, we used flow cytometry to determine if their expression affects progression through the cell cycle. We noted that in the two WT TP53 cell lines with high expression of MDM2 mRNA, MM1s and NCI-H929 ( Figure S1B ), the p53-responsive miRNAs induced a consistent G0/G1 arrest. This effect was observed in $30% of scrambled-transfected cells versus $60% of the cells transfected with miR-192 and 215 and $45% for . By contrast in KMS-28BM cells, retaining WT TP53 but expressing lower levels of MDM2 mRNA ( Figure S1B ), we detected increases of sub-G 1 fractions (indicative of cell death) in cells transfected with miR-192 ($25% sub-G 1 ), 215 (30%), and 194 (12%) at 48 hr after transfection, compared with $3% in control cells transfected with the Scr sequence ( Figure 3I ). At 48 hr after transfection, we also detected increased caspase-3 activity ( Figure 3J ). The differential effect of the miRNAs on TP53 WT cells carrying lower MDM2 mRNA basal expression ( Figure S1B ) led us to analyze MDM2 levels after miRNA transfection ( Figure S3C ). MDM2 mRNA, but not protein, was detected after MM cells transfection. Because MDM2 protein is rapidly autoubiquitinated and degraded through the proteasome pathway (Marine and Lozano, 2010) ; p53 induction is necessary for its detection in MM cells (Stuhmer and Bargou, 2006; Ooi et al., 2009) . Only in one (Mut TP53 RPMI-8226) of six MM cell lines analyzed was MDM2 protein detected without p53 activation (Figures S1A and S1G). We also noted that MDM2 mRNA was downregulated after ectopic expression of these miRNAs, mostly in WT TP53 cells, but to some extent also in Mut TP53 cells (RPMI-8226) ( Figure S3C ). These data were confirmed at the protein level in RPMI-8226 cells where we observed $20% downregulation of MDM2 protein at 72 hr after miRNA transfection ( Figure S3D ). The results indicate that ectopic expression of miR-192, 215, and 194 in WT TP53 cells inhibits cell growth and enhances apoptosis, effects that could be related to MDM2 regulation in MM cells.
Human MDM2 Is a Direct Target of miR-192, 194, and 215 The data thus far demonstrate that the biological functions of miR-192, 215, and 194 in MM cells is p53 dependent. After introduction of these miRNAs the TP53 mRNA level did not change in MM cells but higher CDKN1A and lower MDM2 mRNA levels were observed ( Figure S3 ). Both genes, MDM2 and CDKN1A, are direct targets of p53 but their expression in this case was not preceded by TP53 transcription ( Figure S3B ). Thus, we hypothesized that miR-192, 194 and 215 could target the expression of MDM2. To further examine the effects of these miRNAs on MDM2 protein expression in WT TP53 MM cells, we analyzed the consequences of ectopic Cancer Cell miR-192, 194 , and 215 Target MDM2 in Myeloma Cells (miR-192, 194, 215 , and Scr transfected) at 48 hr of transfection, after first being arrested and synchronized in G2/M phase by Nocodazole for 16 hr. Apoptosis in KMS28BM was evaluated by caspase-3 activity (J). All experiments were performed in triplicate ±SD. -192, miR-194 , and miR-215 at 72 hr after transfection and 12 hr of nongenotoxic activation of p53 by Nutlin-3a (10 mM). Increased expression of these miRs upon transfection was confirmed by qRT-PCR ( Figure S4A) , and the effects on p53, MDM2, and p21 levels were analyzed by western blot ( Figure 4A ). Overexpression of miR-192, 194 , and miR-215 significantly increased the level of p53 and p21 at 12 hr after Nutlin-3a treatment compared with Scr-transfected cells (p < 0.001), as shown by densitometric analysis in Figures 4B and 4C . Expression of MDM2 protein was dramatically decreased in both cell lines (Figures 4A-4C ). Conversely, knockdown by 2 0 -O-me-anti-miR-192-194 and 215 (pool) after 12 hr of Nutlin-3a treatment, as confirmed by qRT-PCR ( Figure S4B ) in TP53 WT cell lines, increased the level of MDM2 protein (p < 0.01), while p21 and p53 protein levels were attenuated (p < 0.01) ( Figure 4B ), as confirmed by densitometry ( Figure 4E ). We also confirmed that MDM2 mRNA levels were strongly reduced in the miR-192-, 194-, and 215-transfected cells at 6 and 12 hr of Nutlin-3a treatment in both cell lines (Figures 4C). These results indicate that miR-192, 194 , and 215 induce the degradation of MDM2 mRNA, confirming that they regulate both, protein and RNA levels. We next tested whether MDM2 is a direct target of these miRNAs by performing a bioinformatics search (Target Scan [Lewis et al., 2003 ]; Pictar Pictar [Krek et al., 2005] ) but were unable to identify the 3 0 UTR of MDM2 as a target. Because the 3 0 UTR of MDM2 is not well conserved across species, we decided to use the RNA22 target prediction program (Miranda et al., 2006) which does not need validated targets for training, and neither requires nor relies on cross-species conservation. RNA22 predicted two miRNA-responsive elements (MREs) for miR-192/215 and two MREs for miR-194 in the 3 0 UTR of human MDM2 (HDM2) ( Figures 4D; Figures S4C-S4G ). To verify that HDM2 is a direct target of HDM2 3 0 UTR containing all MREs ($4K), was cloned into pGL3 basic construct downstream of the luciferase open reading frame ( Figure 4D ). This reporter construct was used to transfect MM1s cells which express the endogenous miRs following upmodulated p53 expression. Increased expression of these miRs upon transfection significantly diminished luciferase expression ( Figure 4D ). We subsequently screened the predicted MREs on the 3 0 UTR of HDM2 mRNA, using luciferase assays with four different constructs carrying the MREs for miR-192/215 and miR-194 ( Figures S4H-S4K) . We observed that expression of each specific MRE reporter construct was specifically downregulated upon transfection of each individual miRNA. Conversely, when we performed luciferase assays using a plasmid harboring the binding sites inactivated by site-directed mutagenesis, we observed a consistent reduction in the inhibitory effects ( Figures S4H-S4K ). We also analyzed the expression of MDM2 mRNA in a panel of CD138+ PCs obtained from MM patients, MGUS patients, and normal donors by RT-PCR ( Figure 4E ). Through KruskalWallis analysis, we found that MDM2 mRNA is significantly upregulated in MM samples (p < 0.001) compared with MGUS samples and normal PCs ( Figure 4E ). Using nonparametric test analysis, we found a significant inverse correlation between miR-192 expression and MDM2 mRNA in MM samples (Sperman r = À0.698, p < 0.0001, n = 33) ( Figure 4F ). -192, 194 , and 215 Re-expression Enhances Sensitivity of WT TP53 MM Cells to Nongenotoxic Activation of p53 In Vitro and In Vivo To determine if re-expression of the miRNAs could enhance sensitivity of WT TP53 MM cells to nongenotoxic activation of p53, we tested MI-219, a highly selective, orally active small-molecule inhibitor of the MDM2-p53 interaction (Shangary et al., 2008) . We first examined whether MI-219 induces p53, MDM2, p21, and Puma upregulation in MM1s cells after miR-192, miR-194, and miR-215 transfection. In cells with forced expression of miR-192 and 215, p53 became detectable even in untreated cells (Figures 5A and 5B) (p < 0.05), confirming previously published data in other cell lines (Georges et al., 2008; Braun et al., 2008) . p53 re-expression and subsequent p21 and Puma upregulation was observed in these cells and in miR-194-transfected cells and is clearly visible following 24 hr of 2.5 mM MI-219 treatment ( Figure 5A ). In control cells (Scr), the treatment was ineffective ( Figure 5A ). Densitometric analysis of p53 and MDM2 protein levels was performed when cells were treated for 24 hr with 2.5, 5, and 10 mM MI-219 ( Figure 5B ). Confirming our previous data, we observed higher p53 accumulation (R2-fold increase, p < 0.001) and dramatic MDM2 downregulation (R3-fold decrease, p < 0.001) in miRNA-transfected cells ( Figure 5B ). These opposing changes in MDM2 and p53 expression levels correlated with higher activation of p53 downstream targets, p21 and Puma ( Figure 5A ). Furthermore, MI-219 induced higher caspase-3 activation in the presence of miR-192, miR-194, and miR-215 (p < 0.001) ( Figure 5C ). Next, we examined whether activation of p53 by MI-219 leads to apoptosis in MM cells. Indeed, treatment with MI-219 induced apoptosis as revealed by Annexin V staining ( Figure 5D ). In cells transfected with a pool of miRNAs, MI-219 effectively (p < 0.0002) induced apoptosis at 2.5 mM (27% ± 3%) and 5 mM (32% ± 3%) while the scrambled control did not. This effect was less significant when using MI-219 at 10 mM (30% ± 5%), though it was enhanced when treatment was combined with miRNAs (55% ± 5%) ( Figure 5D ). Increased concentration of MI-219 did not increase the apoptotic rate of scrambled-transfected cells but caused nonspecific toxicity (data not shown). Because previous studies have shown that MI-219 achieved excellent oral availability, we investigated if, in mouse xenograft models, the combined action of miRNAs and oral MI-219 could suppress tumorigenicity of MM cells. Viable MM1s Gfp+/Luc+ cells (8 3 10 6 ) were injected subcutaneously into the right flank of 40 nude mice. At 3 weeks after injection a group of 32 mice with comparable tumor size were selected and randomly divided into four groups for four independent experiments, using eight mice for each combined treatment ( Figure 5E ). Specifically, we used the combination of oral treatment with 200 mg/kg MI-219 or vehicle control (VE) once a day for 14 days plus direct tumor injection of double-strand RNA scrambled sequence (Scr) or a pool of 194, and 215 (miRs) . Whereas the VE-Scr-treated tumors increased 2-fold in volume in 2 weeks (from 5390 ± 993 mm 3 to 13,500 ± 3200 mm 3 [p < 0.0001]), MI-219/Scr-treated tumors remained static in volume (5390 ± 993 mm 3 to 5400 ± 1200 mm 3 ) ( Figure 5E ). By contrast, mice treated with VE-miRs showed $1.5-fold reduction in tumor size (from 5390 ± 993 mm 3 to
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Cancer Cell Cancer Cell 194, and 215 Target MDM2 Figure 5E ). These findings demonstrate proof-ofconcept for in vivo therapy of MM using combined miRNAs and an MDM2 pharmacological inhibitor.
miR-192 and miR-215, by Antagonizing MDM2 Downregulation, Target IGF-1 and IGF1-R Since our data demonstrate that miR-192, miR-194 , and miR-215 target MDM2, we sought to determine if MDM2 substrates could also be affected. IGF-1R is a known target of MDM2 ubiquitin ligase function (Girnita et al., 2003; Froment et al., 2008) . Therefore, by targeting MDM2, miR-192, 194 , and 215 may indirectly influence the expression of IGF-1R. In MM cells, IGF-1R and its ligand, IGF-1, are key factors in regulation of PC migration into the bone marrow (Qiang et al., 2004; Tai et al., 2003) . We noted that in WT TP53 MM cells, p53 re-expression was strongly associated with downregulation of IGF-1R and IGF-1 ( Figures S5A and S5B ) compared with mutant TP53 MM cells ( Figures S5C and S5D) . We sought to determine the effect of miRNAs on IGF-1R and IGF-1 expression through targeting MDM2. We found that in the presence of miR-192, 215 but not miR-194, IGF-1R and IGF-1 protein levels decreased, as determined by western blot analysis ( Figure 6A ). Furthermore, inhibition of endogenous miR-192/215, using antisense oligonucleotides, combined with 24 hr of Nutlin-3a treatments increased both IGF-1R and IGF-1 levels in MM1s cells ( Figure 6B ). This effect was not seen with miR-194. To determine if the regulation of IGF-1 does affect IGF1R in MM cells, we silenced IGF-1 and-observed upregulation of IGF-1R protein levels at 48 and 72 hr posttreatment ( Figure 6C ). This effect was clearly different from that observed following miRNA transfection ( Figure 6A ). We next tested whether miR-192 and 215 target IGF-1R and IGF-1 directly by generating luciferase reporters containing their 3 0 UTRs. Using Targetscan (Lewis et al., 2003) , Pictar (Krek et al., 2005) , and RNA22 (Miranda et al., 2006 ) searches, we identified several MREs for miR-192 and miR-215 but not for miR-194 in the 3 0 UTR of IGF-1R and IGF-1R mRNAs ( Figures 6D and 6E ). Luciferase activity dropped 40%-50% when these constructs were cotransfected into MM1s cells with miR-192, 215 compared with miR-194 and Scr (Figures 6D and 6E; Figures S5E-S5I ). To determine if in freshly isolated CD-138+ PCs these miRNAs could regulate IGF-1 and IGF-1R expression, we transfected miR-192 and 215 (pool) into PCs of nine patients, and we performed immunofluorescence analysis for IGF-1R and IGF-1 at 48 hr. We observed a significant decrease in IGF-1R and IGF-1 protein expression ( Figures 6F and 6G ). Transfection efficiency was confirmed using RNA Fluorescent Oligo ( Figure 6H ). These results indicate that miR-192 and miR-215 directly target IGF-1R and IGF-1 in MM.
miR-192 and 215 Block MM Migration and Invasion In Vitro and In Vivo
Given the known role of IGF-I and IGF-1R as antiapoptotic factors and in MM migration through endothelial barriers and bone marrow stroma (Qiang et al., 2004; Tai et al., 2003) , we sought to determine if miR-192 and 215 interfere with the chemotactic function of IGF-I and block migration and invasion of MM cells. We first determined that miR-192 and 215 actions on the IGF-1 axis in MM affect both WT TP53 (MM1s) and mutant (RPMI-8226) cell lines ( Figure 7A ) and that the downregulation of both proteins critically affects S6 and AKT phosphorylation in these cells. Next, we found that ectopic expression of miR-192 and 215 in NCI-H929 and RPMI-8226 IGF-1-treated cells was associated with significant decrease in cell adhesion ( Figures S6A and  S6B) , migration, and tissue invasion compared with Scr control. To this end, we used an intraepithelial trans-well migration assay with IGF-1 at various concentrations as attractant and two bone marrow-derived stromal cells, HS-5 (fibroblast-like) and HS-27A (epithelial-like) as cell layer. As shown in Figure 7B and Figure S6C , IGF-1 (50 ng/ml) stimulated migration of MM cells, MM1s, and RPMI-8226. To further examine the role of 215, and 194 in MM cells, we investigated the effect of these miRNAs on migration in vivo, using a previously described homing model (Roccaro et al., 2009) . Nine NOD-SCID mice (for each group) were intravenously injected with 8 3 10 6 of pre-miRNA-
192-, 194-, and 215-or Scr probe-transfected GFP
+ /Luc + MM1S cells. One week later, mice were injected intravenously every week for 4 weeks with an individual miRNA or Scr dissolved in PBS (10 mg for each mouse). After 5 weeks, the homed and proliferated tumors were markedly suppressed in miRNA-treated mice compared with Scr-transfected MM cells (p < 0.01) ( Figure 7C ). At 5 weeks postinjection, we first noted reduced tumor progression, by bioluminescence imaging ( Figure 7D ). Mice injected with Scr-transfected MM1s in addition to serial intravenous injection with Scr showed significant tumor growth, but tumor burden was significantly reduced in mice injected with pre-miR-194 and was nearly nonexistent in mice injected with either pre-miR192 or pre-miR-215 ( Figures 7C and 7D ). In addition, through FACS analysis using human CD-138+ antibody, we analyzed bone marrow engraftment of these cells in injected NOD-SCID mice. We confirmed that Scr-treated mice showed bone marrow engraftment of $25% ± 15% of MM1s cells versus 4% ± 2% for miR-192 and 2% ± 2% for miR-215 animals ( Figure 7E ). The in vivo action of miR-194 was less effective, 12% ± 3% of bone marrow engraftment MM1s cells compared with miR-192 and 215 but still higher than the Scr control ( Figure 7E ). These data indicate that miR-192, 215 but also miR-194 have therapeutic potential not only by affecting proliferation rates in MM cells but also by affecting the homing and migration ability of MM cells. -192, 194 and 215 on endogenous p53, p21, and MDM2 levels (western blots) in MM1s cells treated with MI-219 at different concentrations. Densitometric analysis for p53 in untreated cells and for p53 and MDM2 protein levels in 2.5, 5, and 10 mM MI-219-treated cells is reported (B). All experiments were performed in triplicate ±SD. (C) Apoptotic effect at different concentrations and time points for each miRNA-transfected cells was assessed by caspase-3 activation assay ±SD. (D) Apoptosis associated with the pool of these miRNAs upon MI-219 treatment (24 hr) at different concentration (2.5-10 mM) was evaluated by Annexin V. All experiments were performed in triplicate ±SD. (E) Gfp/Luc + MM1s cells were injected subcutaneously into the flanks of nude mice; at 3 weeks postinjection, mice with comparable tumor sizes were selected for treatment (untreated). In vivo confocal imaging of GFP+/Luc+ MM cells engrafted in athymic nu/nu mice after 2 weeks of combined treatment with oral MI-219 or vehicle (VE) plus pre-microRNA pool or Scr sequence directly into the tumors. Graphic represents the mean of tumors value (mm 2 ) before (3 weeks) and after the treatment (3+2 weeks) ±SD.
Cancer Cell miR-192, 194 , and 215 Target MDM2 in Myeloma Cells re-expression of the three miRNAs, was consistent but not uniform in all samples analyzed. Possibly mechanisms other than alterations to the TP53 gene could influence the sensitivity to MDM2 molecular inhibitors. In seeking an explanation for the lack of expression of these miRNAs in MMs, we noted that the genes for these miRNAs are located in chromosomal regions in MM that are normally characterized by chromosome gain and translocations rather than deletions (Fonseca et al., 2009) . We then explored the methylation status in the promoter of the miR-194-2-192 cluster. By combined bisulfite restriction analysis (COBRA), we detected hypermethylation of the promoter region of this cluster (Region R) ( Figure S7A -192, 194, 215, or Scr. Deletion of six bases in all putative consensus sequences on IGF-1-3 0 UTR abrogates these effect (Del) (D). See also Figure S5 . Bars indicate relative luciferase activity ±SD. All experiments were performed in triplicate.
(F and G) Immunofluorescence using anti-IGF-1R (F) and anti-IGF-1 (G) in red and blue nuclear DNA, from CD-138+ PCs from nine MM patients transfected with miR-192 and miR-215 (pool) or Scr and intensity of the signal was assessed ±SD.
(H) The efficiency of the transfection in the nine samples was evaluated using fluorescent double-strand RNA oligos. Scale bars indicate 25 mM.
Cancer Cell 194, and 215 Target MDM2 in Myeloma Cells of these miRNAs in WT TP53 MM cell lines ( Figure S7C ). Reexpression of the SOCS-1 gene, known to be silenced by hypermethylation in MM cells (Galm et al., 2002) , served as internal control.
DISCUSSION
Complex cytogenetic abnormalities and numeric chromosomal aberrations occur in virtually all multiple myeloma, and in most, if not all, cases of MGUS (Kuehl and Bergsagel, 2002) . Paradoxically, mutations and/or deletion of TP53 occur in only a small percentage of intramedullary MMs and not at all in MGUS (Chng et al., 2007) . Several reports (Teoh et al., 1997; Quesnel et al., 1994) and our data ( Figure 4E ) suggest that MDM2 overexpression in MMs, but not its gene amplification (Quesnel et al., 1994) , could be responsible for p53 inactivation in cells retaining functional p53 pathways. This supports the idea that induction of p53 in this setting might be a suitable treatment for MM. There have been a few reports concerning microRNA deregulation in MM and although not all reported findings were in agreement, they confirmed that such deregulation is important in MM pathogenesis (Pichiorri et al., 2008; Roccaro et al., 2009; Lionetti et al., 2009; Gutié rrez et al., 2010) . Here, we studied the role of miRNAs in the p53 apoptotic pathway upon nongenotoxic activation of p53 in MM cells, using small molecular inhibitors of MDM2 . Upon p53 activation, we identified two related microRNA clusters located in regions considered important for MM (miR-194-2-192 at 11q13.1 and miR-194-1-215 at 1q41.1) (Fonseca et al., 2009) . Furthermore, the knowledge that miRNAs coming from the same cluster can reinforce their action on the same cellular pathways (Garofalo et al., 2009; Ventura et al., 2008) 215 , and Scr RNA oligos and then injected intravenously into mice immediately after transfection. After 1 week, the mice were injected intravenously with miRNAs (10 mg) once a week for 4 weeks, and the bioluminescence intensity was assessed before every injection (C). (D) Representative bioluminescence imaging (BLI) after 5 weeks from the injection. (E) Bone marrow cells from the mice used for the experiment were isolated and human CD-138 positive cells (engrafted cells) were detected using anti-CD-138 antibody by flow cytometry (P2 fraction).
promoter region and definition of a noncanonical p53 consensus site, we have shown that these miRNAs are direct p53 targets. In patient samples, the expression of these miRNAs changed during transition from normal PC, via MGUS to intramedullary MM; these miRNAs were significantly downregulated in a cohort of newly diagnosed MMs versus MGUS; 215, and 194 enhanced colony suppression, cell-cycle arrest, or apoptosis in a p53-dependent manner. We also noted, as in the case of KMS28BM cells, that their biological action could be associated with the MDM2 status in MM cells. The short half-life of MDM2 protein (Marine et al., 2010) and difficulties in analyzing its protein expression in MM cells without p53 activation led to the demonstration that the effect of these miRNAs on MDM2 was clearly detectable after treating WT TP53 MM cells with combined Nutlin-3a and ectopic expression of the miRNAs. In fact, we observed that in treated cells with enforced expression of these miRNAs MDM2 was dramatically downregulated at protein and mRNA levels and this downregulation was inversely associated with higher p53 expression and p21 activation ( Figures 4A-4C ). Luciferase assays using plasmids harboring the MDM2 3 0 UTR sequence strongly confirmed that MDM2 is the direct target of these miRNAs. In a subset of newly diagnosed MMs, elevated levels of MDM2 mRNA were inversely associated with miR-192 expression. We proved, in vivo and in vitro, that the combination of these miRNAs with p53 pharmacological activator (MI-219), leading to MDM2 downregulation and subsequent p53, p21, and Puma upregulation, could be a successful therapeutic strategy. In fact, it produced anti-tumor results that could not be achieved solely by increasing the drug concentration. We also found that miR-192 and miR-215 expression, by overriding MDM2 ubiquitination of IGF-1R (Girnita et al., 2003; Froment et al., 2008) , directly targets the IGF-1 axis in MM cells, controlling mobility and invasive properties of MM cells in vitro and in vivo. We propose a model in which these miRNAs are (1) regulators of the autoregulatory loop, increasing the window of time between p53 apoptotic action and p53 degradation by MDM2; and (2) at the same time targeting the IGF axis, antagonizing the MDM2 ubiquitin ligase function on IGF-1R (Figure 8) .
The hypermethylation status in the promoter of the miR-194-2-192 cluster in MM cell lines could support the hypothesis that the transition from MGUS to MM is favored by clonal selection of cells with aberrant promoter methylation of the miR-194-2-192
cluster. This could be associated with a decreasing ability of p53 to downmodulate MDM2 expression thus tipping the regulatory balance in favor of MDM2 in MM cells. This proposed model (illustrated in Figure S7D ) will require further investigation.
Of note, monoallelic deletion of TP53 in MM, which often seems to occur without mutation on the other allele, is associated with an extremely poor prognosis (Chng et al., 2007) . This supports the idea that a 2-fold decrease in TP53 gene content is associated with tumor progression, which supports the hypothesis that a partial lack of expression of these miRNAs in MMs could create a p53 imbalance with direct biological consequences.
In summary, our results have defined a mechanism of p53 regulation through miRNAs acting on MDM2 expression, providing the basis for the development of miRNA-targeted therapies for MM, as illustrated in Figure 8 .
EXPERIMENTAL PROCEDURES
Collection of Primary Cells Thirty-three newly diagnosed primary MM samples, 14 primary samples from monoclonal gammopathy of undetermined significance (MGUS), and 5 primary samples from healthy donors were obtained from bone marrow aspirates. Written informed consent was obtained in keeping with institutional policies (IRB-approved procurement protocol (2000C0247) at Ohio State University and The University of Turin GIMEMA-MM-03-05, N. EUDRACT 2005-004745-33). Three of the five healthy PCs used were purchased from AllCells LLC (Emeryville, CA).
Luciferase Assays
MM1s cells were cotransfected with 1 mg of pGL3 firefly luciferase reporter vector (see luciferase reporter vector method in Supplemental Information), 0.1 mg of the phRL-SV40 control vector (Promega), and 100 nM miRNA precursors (Ambion) using nucleoporation (LONZA) Cell Line Nucleofector Kit V as previously described. Firefly and Renilla luciferase activities were measured consecutively by using the Dual Luciferase Assay (Promega) 24 hr after transfection. Each reporter plasmid was transfected at least twice (on different days) and each sample was assayed in triplicate.
Mouse Experiments
All animals were housed in the Ohio State University animal facility and the experiments with live animals were approved by our institute animal committee (IACUC 2007-A0146) and conducted following the Ohio State University animal policy in accordance with NIH guidelines. Cancer Cell 194, and 215 Target MDM2 in Myeloma Cells Cancer Cell 18, 367-381, October 19, 2010 ª2010 Elsevier Inc. 379 GFP/Luc + MM1s cells (1 3 10 6 ) were suspended in 0.10 ml of extracellular matrix gel (BD Biosciences) and the mixture was injected subcutaneously into the right flank athymic nu/nu mice. Three weeks after injection, mice with comparable size tumors were treated for 2 weeks with a combination of oral dose of MI-219 (200 mg/kg) or vehicle, once a day for 14 days and miRNAs or scrambled sequence oligos (10 mg) (Ambion), was injected directly into the tumors once a week for 2 weeks. For the NOD-SCID engraftment model Luc+/GFP+ MM.1S cells (8 3 10 6 /mouse) were injected into the tail vein of SCID mice. Treatment started 7 days from tumor cell inoculation, by weekly intravenous injections of miRNAs or scrambled sequence. RNA oligos (Ambion) (10 mg) for four cycles (4 weeks total). For more details, see in vivo experiments in Supplemental Information.
Transfection Method for Primary Cells and MM Cell Lines CD-138+ PCs obtained from new diagnosed MM patients and isolated as previously described were transfected by using nucleoporation (LONZA) Cell Line Nucleofector Kit V (Cat#VCA-1003). MM1s, NCI-H929 cell lines were transfected by using nucleoporation (LONZA) Cell Line Nucleofector Kit V (Cat#VCA-1003). Instead for U266, KMS-28BM, and RPMI-8226, Cell Line Nucleofector Kit C (Cat#VCA-1004) was used. Specifically for primary cells 1 3 10 6 CD-138+ PCs were resuspended in 100 ml V solution and 100 nM miRNA precursors (Ambion) was used for the transfection reaction. For more details, see transfection method for primary cells in Supplemental Information.
Target Screening
In this study, we used three publicly available search engines for target prediction to obtain the putative targets: TargetScan (Release 2.1), http://genes.mit. edu/targetscan, Pictar, http://pictar.bio.nyu.edu, and Rna22, http://cbcsrv. watson.ibm.com/rna22_targets.html. For RNA22 predicted sites, we considered only the heteroduplex with a folding energy > À27 Kcal/mol (Figures S8B-S8E) because we were not able to confirm by luciferase assay the interactions between target gene and miRNAs with a folding energy less that À27 Kcal/mol (data not shown).
ACCESSION NUMBERS
The microarray data have been deposited in the Array Express database, www.ebi.ac.uk/arrayexpress (accession number E-TABM-1037 and E-TABM-1038).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures, references, seven figures, and three tables and can be found online at doi:10.1016/j.ccr. 2010.09.005.
